TOP TEN perturbations for 39714_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39714_at
Selected probe(set): 201312_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39714_at (201312_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)

Relative Expression (log2-ratio):7.6104755
Number of Samples:4 / 2
Experimental lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).

lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)

Relative Expression (log2-ratio):-6.6049805
Number of Samples:2 / 3
Experimental lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; basaloid carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).

MCF-7:2A / MCF-7

Relative Expression (log2-ratio):5.8968725
Number of Samples:4 / 4
Experimental MCF-7:2A
Long-term estrogen deprived breast cancer cells MCF-7, which are resistant to estrogen-deprivation and therefore show an aromatase inhibitor resistantance. MCF-7 is human metastatic cancer cell line derived from the pleural effusion of a patient with adenocarcinoma of the breast. Parental cell line:: MCF-7 Cellosaurus code:
Control MCF-7
Human metastatic cancer cell line derived from the pleural effusion of a patient (69 years old, caucasian) with adenocarcinoma of the breast. Synonyms:MCF 7; MCF.7; MCF7; Michigan Cancer Foundation 7; ssMCF7; MCF7/WT; IBMF-7; MCF7-CTRL Cellosaurus code:

lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)

Relative Expression (log2-ratio):5.750392
Number of Samples:43 / 2
Experimental lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).

MCF-7.5C / MCF-7

Relative Expression (log2-ratio):5.7260704
Number of Samples:3 / 4
Experimental MCF-7.5C
Human metastatic cancer cell line derived from the pleural effusion of a patient with adenocarcinoma of the breast. Long-term estrogen deprived breast cancer cells, which are resistant to estrogen-deprivation and therefore show an aromatase inhibitor resistantance. Parental cell line:: MCF-7 Synonyms:MCF-7 clone 5C; 5C; MCF-7:5C Cellosaurus code:
Control MCF-7
Human metastatic cancer cell line derived from the pleural effusion of a patient (69 years old, caucasian) with adenocarcinoma of the breast. Synonyms:MCF 7; MCF.7; MCF7; Michigan Cancer Foundation 7; ssMCF7; MCF7/WT; IBMF-7; MCF7-CTRL Cellosaurus code:

lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; adenosquamous carcinoma; primary)

Relative Expression (log2-ratio):-5.5242395
Number of Samples:2 / 4
Experimental lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; adenosquamous carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenosquamous carcinoma of the lung (subcutaneously implanted).

lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-4.9196596
Number of Samples:2 / 22
Experimental lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the lung (subcutaneously implanted).

IGF-I study 1 (4h; 5nM; T47D-YA/IRS-1 C20) / IGF-I study 1 (4h; 5nM; T47D-YA/IRS-1 C10)

Relative Expression (log2-ratio):-4.905222
Number of Samples:3 / 3
Experimental IGF-I study 1 (4h; 5nM; T47D-YA/IRS-1 C20)
Human breast cancer cell line T47D-YA/IRS-1 C20 samples collected 4 hours after treatment with 5 nM IGF-I (insulin-like growth factor I). The cell line was maintained in MEM, 5% fetal bovine serum, penicillin/streptomycin, 1X non-essential amino acids, 6 ng/l insulin, 50 ug/ml G418, and 100 ug/ml hygromycin B. Cells were plated at a density of 3x10exp6 in 150 mm dishes overnight, then the media were replaced by SFM (serum-free media) alone for 24 h prior the treatment. After 24 hours, the cells were treated with SFM plus fibronectin (2 ug/ml) and IGF-I for 4 hours.
Control IGF-I study 1 (4h; 5nM; T47D-YA/IRS-1 C10)
Human breast cancer cell line T47D-YA/IRS-1 C10 samples collected 4 hours after treatment with 5 nM IGF-I (insulin-like growth factor I). The cell line was maintained in MEM, 5% fetal bovine serum, penicillin/streptomycin, 1x non-essential amino acids, 6 ng/l insulin, 50 ug/ml G418, and 100 ug/ml hygromycin B. Cells were plated at a density of 3x10exp6 in 150 mm dishes overnight, then the media were replaced by SFM (serum-free media) alone for 24 h prior the treatment. After 24 hours, the cells were treated with SFM plus fibronectin (2 ug/ml) and IGF-I for 4 hours.

RAF1 overexpr. study 1 (retrovirus) / control virus infected MCF7 cell sample

Relative Expression (log2-ratio):-4.8088675
Number of Samples:2 / 2
Experimental RAF1 overexpr. study 1 (retrovirus)
MCF-7 cell line stably transfected with retrovirus containing cDNA for RAF1. The following retroviral construct was used: pLNCRaf-1 contains human Raf-1 cDNA encoding an amino terminally truncated form of Raf-1 that is constitutively active, which is inserted into retroviral vector pLNCX encoding neomycin resistance gene (NeoR). MCF7 cells were maintained in EMEM supplemented with 10% FBS and 20ug/ml insulin.
Control control virus infected MCF7 cell sample
MCF7 cell line transfected with pZipneo retrovirus, which is an empty retroviral vector encoding neomycine resistance gene (NeoR). MCF7 cells were maintained in EMEM supplemented with 10% FBS and 20ug/ml insulin.

IGF-I study 1 (24h; 5nM; T47D-YA/IRS-1 C20) / IGF-I study 1 (24h; 5nM; T47D-YA/IRS-1 C10)

Relative Expression (log2-ratio):-4.6236053
Number of Samples:3 / 3
Experimental IGF-I study 1 (24h; 5nM; T47D-YA/IRS-1 C20)
Human breast cancer cell line T47D-YA/IRS-1 C20 samples collected 24 hours after treatment with 5 nM IGF-I (insulin-like growth factor I). The cell line was maintained in MEM, 5% fetal bovine serum, penicillin/streptomycin, 1X non-essential amino acids, 6 ng/l insulin, 50 ug/ml G418, and 100 ug/ml hygromycin B. Cells were plated at a density of 3x10exp6 in 150 mm dishes overnight, then the media were replaced by SFM (serum-free media) alone for 24 h prior the treatment. After 24 hours, the cells were treated with SFM plus fibronectin (2 ug/ml) and IGF-I for 24 hours.
Control IGF-I study 1 (24h; 5nM; T47D-YA/IRS-1 C10)
Human breast cancer cell line T47D-YA/IRS-1 C10 samples collected 24 hours after treatment with 5 nM IGF-I (insulin-like growth factor I). The cell line was maintained in MEM, 5% fetal bovine serum, penicillin/streptomycin, 1X non-essential amino acids, 6 ng/l insulin, 50 ug/ml G418, and 100 ug/ml hygromycin B. Cells were plated at a density of 3x10exp6 in 150 mm dishes overnight, then the media were replaced by SFM (serum-free media) alone for 24 h prior the treatment. After 24 hours, the cells were treated with SFM plus fibronectin (2 ug/ml) and IGF-I for 24 hours.